Literature DB >> 33463973

Bortezomib-Based Regimens and Plasma Cell Leukemia

Ali Zahit Bolaman1.   

Abstract

Entities:  

Keywords:  Bortezomib; Plasma cell leukemia; Treatment

Mesh：

Substances：

Year:  2021        PMID： 33463973      PMCID： PMC7927453          DOI： 10.4274/tjh.galenos.2021.2020.0679

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN： 1300-7777            Impact factor:   1.831


× No keyword cloud information.
  5 in total

1.  The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.

Authors:  Sos Nalghranyan; Amrit P Singh; Carolina Schinke
Journal:  Am J Hematol       Date:  2019-12-02       Impact factor: 10.047

2.  A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.

Authors:  Yoshihito Horisawa; Tadakazu Kondo; Masakatsu Hishizawa; Kouhei Yamashita; Akifumi Takaori-Kondo
Journal:  Ann Hematol       Date:  2020-04-21       Impact factor: 3.673

Review 3.  European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Authors:  Maria Gavriatopoulou; Pellegrino Musto; Jo Caers; Giampaolo Merlini; Efstathios Kastritis; Niels van de Donk; Francesca Gay; Ute Hegenbart; Roman Hajek; Sonja Zweegman; Benedetto Bruno; Christian Straka; Meletios A Dimopoulos; Hermann Einsele; Mario Boccadoro; Pieter Sonneveld; Monika Engelhardt; Evangelos Terpos
Journal:  Leukemia       Date:  2018-07-23       Impact factor: 11.528

4.  Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.

Authors:  Lohith Gowda; Mithun Shah; Ifra Badar; Qaiser Bashir; Nina Shah; Krina Patel; Rashmi Kanagal-Shamanna; Rohtesh Mehta; Donna M Weber; Hans C Lee; Elisabet E Manasanch; Abdul Shah; Sheeba K Thomas; Simrit Parmar; Yago Nieto; Robert Z Orlowski; Richard Champlin; Muzaffar H Qazilbash
Journal:  Bone Marrow Transplant       Date:  2018-11-16       Impact factor: 5.483

5.  Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study

Authors:  Huijuan Wang; Huixing Zhou; Zhiyao Zhang; Chuanying Geng; Wenming Chen
Journal:  Turk J Haematol       Date:  2019-11-26       Impact factor: 1.831
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.